Biotech Stocks in
Focus (NYSE American: $NNVC) (NYSE: $PFE) (NYSE: $GSK) (NASDAQ: $MRNA)
Can Nanotechnology
offer Better Solutions for COVID, RSV and other Viruses?
August
2, 2024 - Investorideas.com,
a go-to investing platform covering biotech and nanotechnology issues a
snapshot looking at news and developments in the antiviral market, featuring NanoViricides, Inc. (NYSE American: NNVC), a
development stage company that is creating special purpose nanomaterials for
antiviral therapy.
From
COVID to RSV and now Bird Flu, the global threat of viruses is only a headline
away and there is a lot of profit for companies offering solutions.
The
Global
Antiviral Drugs Market is estimated to reach USD 74.75 Bn by 2028, says
Research and Markets and nanotech companies are aiming for a big piece of that
pie.
Talking
about nanotech’s future role in the antiviral market, a recent article in Nature
says, “Nanotechnology with precise
control over the properties and structures of nanomaterials holds tremendous
potential in the field of antiviral applications. The application of
nanotechnology in the antiviral field, including the efficient delivery of
antiviral drugs, the blocking of viral infections, and the activation of immune
responses, offers new strategies and approaches, bringing renewed hope for
infectious disease treatment and prevention.”
According to a
recently released report from Zacks
Small Cap Research, “NanoViricides (NYSE American: NNVC) Broad Spectrum Technology Represents Potential Paradigm Shift in
Viral Therapy.”
Continued: “NanoViricides is a
biopharmaceutical company developing anti-viral therapeutics based on its
proprietary nanoviricide technology. A Phase 1 safety study of the company’s
lead asset, NV-387, was recently completed and we anticipate results from the
study being available in the second half of 2024. A Phase 2 clinical trial in
Respiratory Syncytial Virus (RSV) is currently being planned. As opposed to
currently available antiviral therapies in which each compound is only active
against a unique type of virus, NanoViricides has disclosed preclinical results
for NV-387 in multiple viral models that demonstrates the broad-spectrum action
of the compound. These results could represent a new paradigm in viral
therapy.”
Paid news dissemination on behalf of NanoViricides
Read
this news, featuring NNVC in full at https://www.investorideas.com/news/2024/nanotech/08021Better-Solutions-for-Viruses.asp
On July 24th
NanoViricides issued a
reminder on the strong safety and effectiveness against
coronaviruses demonstrated by its lead clinical drug candidate NV-387.
"President
Joe Biden has thankfully recovered from the bout of COVID caused by a new
variant," said Anil R. Diwan, PhD, President and Executive Chairman of the
Company, adding, "This again brings into limelight the lack of strong
drugs against COVID; a gap that NV-387 is expected to fulfill."
From the news: There is clearly a need for a highly
effective and preferably oral drug against COVID. COVID in the USA has become a
biannual affair, with ever new, different variants leading each new wave. COVID
continues to claim annually greater numbers of lives and hospitalizations than
Influenza.
We believe it
is important to bring to the attention of everyone how strong the activity of
NV-387 in animal studies against coronaviruses has been, even compared with the
most effective anti-coronavirus drug, namely, remdesivir (Veklury® Gilead).
We have
studied a lethal lung infection in rats with a coronavirus that results in the
same pathology but only milder than the delta variant, in humans as compared to
COVID.
In one study,
NV-387 intravenous injection (I.V.) treatment led to a substantial improvement
in survival, of 180%, as compared to Remdesivir
(Pfizer Inc. NYSE:PFE), of only 50%.
Continued: We thereafter developed an oral
formulation of NV-387 and studied its effect in comparison to the NV-387 I.V.
treatment.
The results
indicate that NV-387 oral drug is expected to be highly effective in treatment
of COVID infections. The results also suggest that for hospitalized patients,
NV-387 injectable form would be preferable over the oral form.
The focus
throughout the pandemic has been primarily on antibodies and vaccines.
Antibodies as drugs are now clearly evidenced to be not useful for a long
enough period to provide major public health benefits. The limits of vaccines
and vaccination campaigns both have also become clearly evident. In this
scenario, Paxlovid™ (Pfizer Inc. NYSE:PFE), remains the only oral
drug available, in spite of its known weak clinical effectiveness, which is
evidenced in clinical trials that showed that in otherwise healthy adults it
was not shown to be better than placebo.
Additional
drug development for COVID treatment is clearly a public health necessity.
NV-387 is possibly the most advanced drug candidate that has demonstrated both
strong activity and safety in a number of studies towards regulatory approvals.
NV-387 has
undergone Phase I human clinical trial to evaluate the safety and tolerability
in the form of two different oral formulations, namely, NV-CoV-2 Oral Syrup,
and NV-CoV-2 Oral Gummies in India. There were no dropouts and there were no
reported adverse events, indicating excellent safety and tolerability of NV-387
even at high dosage levels.
We have also
found that NV-387 has a very wide antiviral spectrum, covering at least the
following: Coronaviruses, RSV, Influenza, and Poxviruses (Smallpox/Mpox). This
indicates that antiviral drug resistance against NV-387 would be highly
unlikely.
Reporting on Pfizer’s
(NYSE:PFE) Paxlovid™, Reuters
recently noted, “A 15-day course of Pfizer's
(PFE.N), opens new tab COVID-19 antiviral treatment Paxlovid did not relieve
symptoms of long COVID, according a study by Stanford University researchers.”
Continued: Currently, there are no proven
treatments specifically for long COVID in which a host of symptoms can last for
many months after initial coronavirus infection.
Scientists and
patients had hoped that Pfizer's two-drug oral treatment would ease symptoms of
long COVID after anecdotal reports of patients who said Paxlovid helped them.
Continued: But the15-week, 155-participant
study failed to show that a 15-day course helped more than a placebo in
reducing fatigue, brain fog, shortness of breath, body aches, or
gastrointestinal or cardiovascular symptoms. Trial participants, on average,
had been sick more than 16 months before enrolling in the trial.
"We did
not see a measurable difference based on patient reported outcomes in the six
composite symptoms together," Stanford Medicine Professor, Dr. Upinder
Singh said in an interview. "We didn't see a benefit in individual
symptoms either."
The vaccine
market is shifting after companies were making record profits during COVID, but
there is still big money at play and new viruses to address.
FiercePharma reported,
“GSK (NYSE:
GSK) reported sales of 1.24 billion euros ($1.53 billion) in
the third and fourth quarter for its RSV shot Arexvy, which is for people ages
60 and older. Meanwhile, Sanofi and AZ-partnered pediatric shot Beyfortus
generated 547 million euros ($592 million) in sales, a figure expected to
double in 2024.”
Continued: “Industry experts who we’ve spoken
to believe the global market opportunity for RSV vaccines is substantial,
possibly reaching ($9 billion to $10 billion) and supporting attractive growth
for leading companies,” Third Bridge’s Brown noted.
Zacks
Equity Research looking at the biotech sector earlier
this week, commented on Moderna, Inc. (NASDAQ:MRNA), once the darling of the COVID era, noting it is diversifying
its pipeline. “Moderna recently obtained a significant boost with the FDA
approval of RSV vaccine mResvia to prevent RSV-associated lower respiratory
tract disease (RSV-LRTD) in older adults aged 60 years and above. The vaccine
is scheduled for commercial launch during the 2024 fall season.
The company
plans to launch several new marketed products over the next five years. With
these potential launches, management aims to not only boost its revenues but
also reduce dependence on Spikevax. As one of the first-ever COVID-19 vaccine
makers, Moderna’s robust product sales boosted cash resources and enabled it to
accelerate its pipeline development. The company is developing cytomegalovirus,
cancer and influenza vaccines in late-stage studies.”
Vaccines are
not the only answer to virus treatment, so big pharma will be looking to innovate to
capture market share and new opportunities.
NanoViricides, Inc. (NYSE American: NNVC) said in its most recent news, “We are now seeking collaborations with Pharma companies to
bring this remarkable drug, NV-387, towards regulatory approvals for multiple
antiviral indications.”
NanoViricides stated
earlier in July, “We are living in a world with many
viruses that threaten our health. The current model of developing a drug
against each virus separately is expensive and untenable with the myriad of
viruses affecting humans that are gaining major foothold.”
“NV-387 turns
this drug development model on its head, with a single drug that would be
effective against many of these viruses. It simplifies preparedness for
pandemics. It reduces cost of development to a single drug instance.”
Research and find more biotech stocks
at Investorideas.com
https://www.investorideas.com/BIS/Stock_List.asp
Research Nanotech stocks at
Investorideas
https://www.investorideas.com/Nanotechnology/Stocks_List.asp
About Investorideas.com
Investorideas.com is the go-to platform for big investing ideas. From
breaking stock news to top-rated investing podcasts, we cover it all. Our
original branded content includes podcasts such as Exploring Mining, Cleantech,
Crypto Corner, Cannabis News, and the AI Eye. We also create free investor
stock directories for sectors including mining, crypto, renewable energy,
gaming, biotech, tech, sports and more.
Disclaimer/Disclosure: This news
article featuring NanoViricides, Inc. (NYSE American: NNVC) is a paid for news
release creation and dissemination on Investorideas.com. Our site does not
make recommendations for purchases or sale of stocks, services or
products. This is not investment
opinion: Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each
country. Privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact
Investorideas.com
800-665-0411
Biotech Industry Stocks- investing ideas in biotechnology
stocks, medical technology and life sciences
Get more biotech and medical tech news,
articles, podcasts and stock directories
Nanotech Stocks- investing ideas in nanotechnology stocks,
Get more Nanotech
news, articles, and stock directories
